Isolation of COVID-19-Specific neutralizing Antibodies from COVID-19 patients for therapeutic and prophylactic use

Isolation of COVID-19-Specific neutralizing Antibodies from COVID-19 patients for therapeutic and prophylactic use - The COSCA study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55316

Enrollment

200

Registered

2020-03-17

Start date

2020-03-23

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronaviral infection COVID-19

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -written informed consent to participate in the study and store samples -age between 18 and 75 years - PCR confirmed SARS-CoV-2 infection - able to visit the Amsterdam UMC, location AMC 3-8 weeks after onset of COVID-19 symptoms. In the absence of symptoms, patients will visit the Amsterdam UMC, location AMC 3-8 weeks after PCR confirmation. A home visit by the study team is a possibility when the patient is unable to travel to the Amsterdam UMC.

Exclusion criteria

Exclusion criteria: -mental disorder that in the view of the investigator would interfere with adherence to the treatment or the study procedures, or the decision to participate in the study. -use of immunosuppressive medication (equivalent of > 7.5mg prednisolone / day). Note: Patients with only a short course of immunosuppressive medication can still participate.

Design outcomes

Primary

Measure	Time frame
For objective 1, the main endpoints are the percentage COVID-19 spike protein positive memory B cells and the neutralization potency of monoclonal antibodies derived from COVID-19 spike protein positive memory B cells. For objective 2 the main endpoint are the percentage Coronavirus (CoV) cross-reactive memory B cells and the neutralization potency and breadth of monoclonal antibodies derived from CoV cross-reactive memory B cells.	—

Measure

Time frame

For objective 1, the main endpoints are the percentage COVID-19 spike protein positive memory B cells and the neutralization potency of monoclonal antibodies derived from COVID-19 spike protein positive memory B cells. For objective 2 the main endpoint are the percentage Coronavirus (CoV) cross-reactive memory B cells and the neutralization potency and breadth of monoclonal antibodies derived from CoV cross-reactive memory B cells.

—

Countries

Netherlands

Outcome results